FluoGuide aktie (FLUO) | Pressmeddelande - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

•Investeringsmöjlighet: Bli delägare i global ledare inom AI-baserad videoanalys på säkerhetsmarknaden (annons)

Pressmeddelanden från FluoGuide

 Bevaka pressreleaser
Kurs från TradingView
StartNyheterPressreleaserRiktkurserInsynshandelBlankningAnalyserBloggarVideosPodcasts

Publication of positive phase II clinical data for FG001 in patients with head and neck cancer

Copenhagen, Denmark, 19 November 2024 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce publication of the first clinica...

MFN • 19 Nov 13:43

FluoGuide A/S issue warrants to board member, CMO and CFO

Copenhagen, Denmark, 12 November 2024 – FluoGuide A/S (“FluoGuide” or the “Company”) announces issuing of 37,500 warrants to board member Do...

MFN • 12 Nov 18:23

Roger Gunnarsson resigns as board member due to return to a full-time investment banking career, which precludes him from holding board position in FluoGuide

Copenhagen, Denmark – FluoGuide A/S (“FluoGuide” or the “Company”), a biothech company specializing in precision cancer surgery, announces t...

MFN • 21 Oct 16:13

FluoGuide A/S submits Clinical Trial Application for phase II trial in head and neck cancer

Copenhagen, Denmark - FluoGuide A/S (“FluoGuide” or the “Company”), a biothech company specializing in precision cancer surgery, today annou...

MFN • 07 Oct 13:13

FluoGuide A/S publishes interim report for the period January – June 2024

Copenhagen, Denmark, 29 August 2024 – FluoGuide A/S (“FluoGuide” or the “Company”) today releases its results for the period 1 January – 30 ...

MFN • 29 Aug 08:55

FluoGuide appoints Jens Ellrich as Chief Medical Officer

Copenhagen, Denmark – FluoGuide A/S (“FluoGuide” or the “Company”), a biotech company specializing in precision cancer surgery, announces th...

MFN • 26 Aug 09:05

FluoGuide has completed a directed share issue to existing and new investors raising proceeds of SEK 60 million

Copenhagen, Denmark, 18 June 2024. FluoGuide A/S, a developer of surgical precision solutions within oncology (“FluoGuide” or the “Company”)...

MFN • 18 Jun 23:12

FluoGuide intends to carry out a directed share issue of approximately SEK 60 million

Copenhagen, Denmark, 18 June 2024. FluoGuide A/S, a developer of surgical precision solutions within oncology (“FluoGuide” or the “Company”)...

MFN • 18 Jun 17:31

FluoGuide A/S publishes interim report for the period January – March 2024

Copenhagen, Denmark, 30 May 2024 – FluoGuide A/S (“FluoGuide” or the “Company”) today releases its results for the period 1 January – 31 Mar...

MFN • 30 May 08:51

FluoGuide selects laser system for photothermal cancer therapy with FG001

Copenhagen, Denmark – FluoGuide A/S (“FluoGuide” or the “Company”), a biotech company specializing in precision cancer surgery, has chosen l...

MFN • 27 May 09:40

Minutes from Annual General Meeting in FluoGuide A/S

Copenhagen, Denmark, 20 March 2024 – FluoGuide A/S (“FluoGuide” or the “Company”) held its annual general meeting on 20 March 2024.

MFN • 20 Mar 14:25

Chief Financial Officer (CFO) Ole Larsen buys shares

Copenhagen, Denmark – 13 March 2024 – FluoGuide A/S (“FluoGuide” or the “Company”) today announces that Ole Larsen (CFO) has bought shares.

MFN • 13 Mar 11:17

FluoGuide enters collaboration within robot assisted head and neck cancer surgery with Intuitive Surgical, a world leading robotic-assisted surgery company

FluoGuide enters collaboration within robot assisted head and neck cancer surgery with Intuitive Surgical, a world leading robotic-assisted ...

MFN • 12 Mar 12:12

Notice of Annual General Meeting in FluoGuide A/S

Notice of Annual General Meeting in FluoGuide A/S

MFN • 01 Mar 12:41

FluoGuide A/S publishes year-end and annual report for the fiscal year 2023

FluoGuide A/S publishes year-end and annual report for the fiscal year 2023

MFN • 28 Feb 08:10

FluoGuide A/S issues warrants to CFO

FluoGuide A/S issues warrants to CFO

MFN • 23 Feb 16:02

FluoGuide provides strategic update and outlines development plans towards commercialization of FG001

FluoGuide provides strategic update and outlines development plans towards commercialization of FG001

MFN • 08 Jan 11:33

Chief Development Officer (CDO) Grethe Nørskov Rasmussen sells shares

Copenhagen, Denmark, 9 December 2023 – FluoGuide A/S (“FluoGuide” or the “Company”) today announces that Grethe Nørskov Rasmussen (CDO) has ...

MFN • 09 Dec 2023 16:17

FluoGuide raises SEK 12 million through exercise of warrants

Copenhagen, Denmark – FluoGuide A/S (“FluoGuide” or the “Company”), a pioneer in the cutting-edge field of precision cancer surgery, today a...

MFN • 08 Dec 2023 09:55

FluoGuide A/S publishes interim report for the period January – September 2023

Copenhagen, Denmark, 29 November 2023 – FluoGuide A/S (“FluoGuide” or the “Company”) today releases its results for the period 1 January – 3...

MFN • 29 Nov 2023 08:00

FluoGuide announces FG001 meets primary endpoint in phase llb trial in aggressive brain cancer

FluoGuide announces FG001 meets primary endpoint in phase llb trial in aggressive brain cancer

MFN • 13 Nov 2023 08:35

FluoGuide confirms positive topline results from phase lla trial of FG001 in head & neck cancer at International Academy of Oral Oncology conference

FluoGuide confirms positive topline results from phase lla trial of FG001 in head & neck cancer at International Academy of Oral Oncology co...

MFN • 06 Nov 2023 10:01

FluoGuide receives FDA Orphan Drug Designation for FG001 in high-grade glioma

FluoGuide receives FDA Orphan Drug Designation for FG001 in high-grade glioma

MFN • 03 Oct 2023 10:34

FluoGuide receives Danish award for the best share price performance since IPO

Copenhagen, Denmark, 8 September 2023 – FluoGuide A/S (“FluoGuide” or the “Company”), a pioneer in the cutting-edge field of precision cance...

MFN • 08 Sep 2023 12:00

Positive interim data from phase lla trial of FG001 in head & neck cancer presented as a case report at the World Molecular Imaging Congress in Prague

Copenhagen, Denmark, 7 September 2023 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to see the first data from FG001 study guidi...

MFN • 07 Sep 2023 14:32

FluoGuide A/S publishes interim report for the period January – June 2023

Copenhagen, Denmark, 30 August 2023 – FluoGuide A/S (“FluoGuide” or the “Company”) today releases its results for the period 1 January – 30 ...

MFN • 30 Aug 2023 08:05

FluoGuide reports further positive interim data from phase IIa trial of FG001 in head & neck cancer

FluoGuide reports further positive interim data from phase IIa trial of FG001 in head & neck cancer

MFN • 29 Aug 2023 09:32

FluoGuide completes patient enrollment and treatment in FG001 phase llb clinical trial in aggressive brain cancer

FluoGuide completes patient enrollment and treatment in FG001 phase llb clinical trial in aggressive brain cancer

MFN • 28 Aug 2023 16:15

FluoGuide A/S issues warrants to the investors participating in the directed share issue

Copenhagen, Denmark, 28 August 2023 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that the issue of 211,389 warrants...

MFN • 28 Aug 2023 12:53

FluoGuide A/S issues warrants to Board members, management and employees

Copenhagen, Denmark, 31 July 2023 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that based on the approved Incentive...

MFN • 31 Jul 2023 18:42

Minutes from Extraordinary General Meeting in FluoGuide A/S

Copenhagen, Denmark, 25 July 2023 – FluoGuide A/S (“FluoGuide” or the “Company”) held an extraordinary general meeting on 25 July 2023.

MFN • 25 Jul 2023 16:12

FluoGuide convenes an extraordinary general meeting

Copenhagen, Denmark, 7 July 2023 – FluoGuide A/S (“FluoGuide” or the “Company”) hereby invites shareholders to participate in an extraordina...

MFN • 07 Jul 2023 13:35

FluoGuide completes a Directed Share Issue raising SEK 15 million

FluoGuide A/S (“FluoGuide” or the “Company”), a Danish biotech company that pioneers precision cancer surgery, is pleased to announce that t...

MFN • 05 Jul 2023 13:33

FluoGuide announces positive interim results from phase IIa trial of FG001 in head & neck cancer

FluoGuide A/S (“FluoGuide” or the “Company”), a Danish biotech company that pioneers precision cancer surgery, is pleased to announce positi...

MFN • 20 Jun 2023 08:18

FluoGuide announces positive topline results from phase IIa trial of FG001 in lung cancer

FluoGuide A/S (“FluoGuide” or the “Company”), a Danish biotech company that pioneers precision cancer surgery, is pleased to announce positi...

MFN • 07 Jun 2023 09:00

FluoGuide A/S publishes interim report for the period January – March 2023

Copenhagen, Denmark, 31 May 2023 – FluoGuide A/S (“FluoGuide” or the “Company”) today releases its results for the period 1 January – 31 Mar...

MFN • 31 May 2023 08:20

FluoGuide provides update on strong clinical trial progress

FluoGuide A/S (“FluoGuide” or the “Company”), a Danish biotech company that pioneers precision cancer surgery, is pleased to provide an upda...

MFN • 24 May 2023 09:52

FluoGuide awarded prestigious grant together with two academic partners

FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that Innovation Fund Denmark (Innovationsfonden) has awarded its largest...

MFN • 21 Mar 2023 12:04

Minutes from Annual General Meeting in FluoGuide A/S

Copenhagen, Denmark, 21 March 2023 – FluoGuide A/S (“FluoGuide” or the “Company”) held its annual general meeting on 21 March 2023.

MFN • 21 Mar 2023 11:47

Notice of Annual General Meeting in FluoGuide A/S

Notice of Annual General Meeting in FluoGuide A/S

MFN • 06 Mar 2023 22:27

FluoGuide A/S publishes Year-end and annual report for the fiscal year 2022

FluoGuide A/S (“FluoGuide” or the “Company”) hereby publishes its annual report for the fiscal year 2022.

MFN • 28 Feb 2023 09:00

FluoGuide updates on recruitment in phase IIb aggressive brain cancer trial with FG001

FluoGuide A/S (“FluoGuide” or the “Company”) provides an update on the clinical timelines for the ongoing clinical phase IIb trial of FG001 ...

MFN • 27 Feb 2023 09:25

FluoGuide appoints Ole Larsen as CFO

FluoGuide A/S (“FluoGuide” or the “Company”) has appointed Ole Larsen as Chief Financial Officer (“CFO”).

MFN • 02 Feb 2023 08:40

CFO acquired shares in FluoGuide

FluoGuide A/S (“FluoGuide” or the “Company”) announce that the CFO of FluoGuide, Henrik Hang, has acquired 500 shares in the Company on 24 J...

MFN • 25 Jan 2023 13:50

FluoGuide releases positive interim result of FG001 in head and neck cancer

Copenhagen, Denmark, 9 January 2023 - FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce the positive interim result of FG0...

Cision • 09 Jan 2023 10:30

FluoGuide A/S publishes interim report for the period January – September 2022

Copenhagen, Denmark, 24 November 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) today releases its results for the period 1 January – 3...

Cision • 24 Nov 2022 07:45

FluoGuide has enrolled the first patient in the phase IIa trial in head and neck cancer

Copenhagen, Denmark, 21 November 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that the company has enrolled th...

Cision • 21 Nov 2022 13:06

FluoGuide reaches milestone with FG001 for phase III clinical supply

Copenhagen, Denmark, 8 November 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to inform that the first large scale batch fo...

Cision • 08 Nov 2022 08:33

FluoGuide releases positive interim result of FG001-CT002, a phase IIa trial evaluating FG001 in patients with non-small cell lung cancer (NSCLC) undergoing surgery

Copenhagen, Denmark, 6 November 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that FG001 lights up in 5 out of ...

Cision • 06 Nov 2022 15:53

FluoGuide has enrolled the first patient in the phase IIb trial in aggressive brain cancer

Copenhagen, Denmark, 20 October 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that the first patient has now en...

Cision • 20 Oct 2022 12:07

Presentation of phase l/lla clinical data of FG001 in aggressive brain cancer at the European Congress of Neurosurgery 2022

Copenhagen, Denmark, 6 October 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to inform that the Principal Investigator, Chi...

Cision • 06 Oct 2022 09:54

The excellent phase I/IIa clinical data of FG001 in aggressive brain cancer was presented at the World Molecular Imaging Congress

Copenhagen, Denmark, 3 October 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to inform of presentation of the outstanding c...

Cision • 03 Oct 2022 13:01

FluoGuide has received approval from the Danish Medicines Agency to initiate phase II trial with FG001 in head and neck cancer

Copenhagen, Denmark, 6 September 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) is delighted to announce that the company has received ...

Cision • 06 Sep 2022 13:46

FluoGuide appoints new CFO

Copenhagen, Denmark, 31 August 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) has today appointed Henrik Hang as Chief Financial Office...

Cision • 31 Aug 2022 15:01

FluoGuide receives permission to start phase IIb trial in aggressive brain cancer

Copenhagen, Denmark, 30 August 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that the company now has received ...

Cision • 30 Aug 2022 09:28

FluoGuide A/S publishes interim report for the period January – June 2022

Copenhagen, Denmark, 25 August 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) today releases its results for the period 1 January – 30 ...

Cision • 25 Aug 2022 09:23

FluoGuide’s update on FG001’s clinical development

Copenhagen, Denmark, 24 August 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) provides an update on the clinical development of FG001.

Cision • 24 Aug 2022 12:23

FluoGuide has submitted a Clinical Trial Application (CTA) to the Danish Medicines Agency to initiate phase II trial with FG001 in head and neck cancer

Copenhagen, Denmark 23 August2022– FluoGuide A/S (“FluoGuide” or the “Company”) is delighted to announce that the company has submitted a CT...

Cision • 23 Aug 2022 08:18

Publication of clinical data confirming uPAR as an attractive target for guiding surgery in head and neck cancer

Copenhagen, Denmark, 22 August 2022. FluoGuide A/S ("FluoGuide" or the “Company”) is pleased to announce a publication of clinical data that...

Cision • 22 Aug 2022 15:13

FluoGuide A/S publishes interim report for the period January – March 2022

Copenhagen, Denmark, 31 May 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) today releases its results for the period 1 January – 31 Mar...

Cision • 31 May 2022 08:24

FluoGuide invites to presentation of FG001 results from the first clinical trial in aggressive brain cancer on 17 May 2022

Copenhagen, Denmark, 6 May 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) invites to a presentation of the results from the clinical tr...

Cision • 06 May 2022 12:41

Annual General Meeting Copenhagen, Denmark, 2 May 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) hereby convenes an annual general meeting to be held on 18 May 2022.

To the shareholders of FluoGuide A/S

Cision • 02 May 2022 12:29

FluoGuide announces positive top line result from the first part of the ongoing clinical phase I/II trial testing the safety and performance of FG001 in lightening up aggressive brain cancer

Copenhagen, Denmark, 01.04.2022 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that FG001 has been shown safe and wel...

Cision • 01 Apr 2022 12:29

FluoGuide A/S publishes Year-end and annual report for the fiscal year 2021

Copenhagen, Denmark, 30 March 2022  – FluoGuide A/S (“FluoGuide” or the “Company”) hereby publishes its annual report for the fiscal year 20...

Cision • 30 Mar 2022 08:28

FluoGuide A/S issue warrants to employees and management

Copenhagen, Denmark, 29 March 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that based on the approved Incentiv...

Cision • 29 Mar 2022 18:56

FluoGuide has received approval from the Danish Medicines Agency to initiate phase II trial with FG001 in lung cancer

Copenhagen, Denmark, 24 March 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) is delighted to announce that the company has received app...

Cision • 24 Mar 2022 12:24

FluoGuide has been awarded a grant together with Rigshospitalet (DK) to conduct a phase II trial with FG001 in patients with less aggressive brain cancers

Copenhagen, Denmark, 18 March 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce a grant of total 945 KDKK to conduc...

Cision • 18 Mar 2022 10:27

FluoGuide has completed a directed share issue raising approximately SEK 25 million

Copenhagen, Denmark, 10 March 2022 – FluoGuide A/S (publ) a developer of surgical precision solutions within oncology (“FluoGuide” or the “C...

Cision • 10 Mar 2022 20:58

FluoGuide intends to carry out a directed share issue of approximately SEK 25 million

Copenhagen, Denmark, 17:31 CEST, 10 March 2022 – FluoGuide A/S (publ), a developer of surgical precision solutions within oncology (“FluoGui...

Cision • 10 Mar 2022 17:32

FluoGuide has submitted a Clinical Trial Application (CTA) to the Danish Medicines Agency to initiate phase II trial with FG001 in lung cancer

Copenhagen, Denmark, 22 December 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is delighted to announce that the company has submitted...

Cision • 22 Dec 2021 11:57

ABG Sundal Collier initiates equity research on FluoGuide

ABG Sundal Collier initiates equity research on FluoGuide

Cision • 19 Nov 2021 08:56

FluoGuide A/S publishes interim report for the period January – September 2021

Copenhagen, Denmark, 15 November 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) today releases its results for the period 1 January – 3...

Cision • 15 Nov 2021 08:21

FluoGuide selects lung cancer as the next indication for FG001 and will initiate phase II trial in the beginning of 2022

Copenhagen, Denmark, 10 November 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is delighted to announce that the company has selected ...

Cision • 10 Nov 2021 08:20

Publication of a case report showing first promising clinical data on FG001s use in treatment of meningioma brain tumor

Copenhagen, Denmark, 9 November 2021. FluoGuide A/S ("FluoGuide" or the “Company”) is pleased to announce the publication of a clinical case...

Cision • 09 Nov 2021 09:24

FluoGuide initiates preclinical development with FG002

Copenhagen, Denmark, 1 November 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) today is pleased to announce the initiation of the precl...

Cision • 01 Nov 2021 11:25

Redeye initiates commissioned research on FluoGuide

Copenhagen, Denmark, 12 October 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) has entered into an agreement with the Swedish investmen...

Cision • 12 Oct 2021 10:08

FG001 is proven safe in patients undergoing surgery for cancer - a significant milestone for FluoGuide to further advance clinical development in aggressive brain cancer and in a prevalent indication

Copenhagen, Denmark, 8 October 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that FG001 has been concluded to b...

Cision • 08 Oct 2021 15:57

Executive management members and members of the Board of Directors buys shares and board member Shomit Ghose sells shares

Copenhagen, Denmark, 14 September 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) today announces that Morten Albrechtsen (CEO), Andreas...

Cision • 14 Sep 2021 11:54

FluoGuide proceeds to seventh dose level (36 mg) with FG001 in the ongoing clinical phase I/II trial following continued improvement of tumor illumination with increasing doses

Copenhagen, Denmark, 14 September 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that FG001 was well tolerated, ...

Cision • 14 Sep 2021 08:01

FluoGuide announces regulatory approval from Swedish Authorities (MPA and Ethics committee) to commence Phase II clinical trial with FG001 in guiding surgery of high grade glioma in Sweden

Copenhagen, Denmark, 26 August 2021 – FluoGuide A/S (“FluoGuide” or “the Company”) is pleased to announce that the company has received regu...

Cision • 26 Aug 2021 09:47

FluoGuide A/S publishes interim report for the period January – June 2021

Copenhagen, Denmark, 25 August 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) today releases its results for the period 1 January – 30 ...

Cision • 25 Aug 2021 08:24

Publication of promising preclinical data on FG001s effect in treatment of cancer

Copenhagen, Denmark, 23 August 2021. FluoGuide A/S ("FluoGuide" or the “Company”) is pleased to announce the first publication of preclinica...

Cision • 23 Aug 2021 08:45

FluoGuide receives tranche of EUR 750,000 under its ongoing grant from EIC Accelerator - SME Instrument under European Union for FG001

Copenhagen, Denmark, 20 August 2021 FluoGuide A/S ("FluoGuide" or the “Company”) is pleased to announce that the Company has received a tran...

Cision • 20 Aug 2021 08:35

FluoGuide proceeds to sixth dose level with FG001 in the ongoing clinical phase I/II trial following strong data from the concluded evening dosing

Copenhagen, Denmark, 17 August 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to report that FG001 was well tolerated, and l...

Cision • 17 Aug 2021 12:26

FluoGuide enters agreement with Swedish university hospital for the second phase of the ongoing FG001 clinical trial (correction)

Correction: The subject line in e-mail recipients contained a wrong text.

Cision • 30 Jun 2021 10:58

FluoGuide enters agreement with Swedish university hospital for the second phase of the ongoing FG001 clinical trial

Copenhagen, Denmark, 30 June 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that the Company has entered into an...

Cision • 30 Jun 2021 10:10

Minutes from Extraordinary General Meeting in FluoGuide A/S

Copenhagen, Denmark, 21 June 2021 – FluoGuide A/S, CVR no.

Cision • 21 Jun 2021 15:56

New article reveals promising results of using FluoGuide’s FG002 technology in guiding surgical removal of cancer

Copenhagen, Denmark, 17 June 2021 FluoGuide A/S ("FluoGuide" or the “Company”) is pleased to announce that promising preclinical data with t...

Cision • 17 Jun 2021 07:55

New Board member proposed and invitation for Extraordinary General Meeting

Copenhagen, Denmark, 4 June 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) proposes the election of Mats Thorén as new board member and...

Cision • 04 Jun 2021 10:25

FluoGuide A/S - Flagging message

Copenhagen, Denmark, 1 June 2021

Cision • 01 Jun 2021 13:23

FluoGuide issue warrants to employees, management, and Board of Directors

Copenhagen, Denmark, 28 May 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that based on the approved Incentive ...

Cision • 28 May 2021 09:04

FluoGuide A/S publishes interim report for the period January – March 2021

Copenhagen, Denmark, 26 May 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) today releases its results for the period 1 January – 31 Mar...

Cision • 26 May 2021 08:32

FluoGuide has received green light to proceed to the next dose level with FG001 in the ongoing clinical phase I/II trial in patients undergoing surgical treatment of high grade glioma.

Copenhagen, Denmark, 18 May 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that the dose escalation committee ha...

Cision • 18 May 2021 08:00

FluoGuide has received approval to commence with FG001 in evening dosing in the ongoing clinical phase I/II trial in patients with high grade glioma

Copenhagen, Denmark, 12 May 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that the Danish Medicines Agency and ...

Cision • 12 May 2021 09:28

FluoGuide has completed a directed share issue raising SEK 75 million

Copenhagen, Denmark, 12 May 2021 – FluoGuide A/S (publ a developer of surgical precision solutions within oncology (“FluoGuide” or the “Comp...

Cision • 12 May 2021 07:44

FluoGuide intends to carry out a directed share issue of approximately SEK 75 million

Copenhagen, Denmark, 17:31 CEST, 11 May 2021 – FluoGuide A/S (publ), a developer of surgical precision solutions within oncology (“FluoGuide...

Cision • 11 May 2021 17:36

FluoGuide has received green light to proceed to fifth dose level with FG001 in the ongoing clinical phase I/II trial in patients with high grade glioma

Copenhagen, Denmark, 8 April 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that the dose escalation committee h...

Cision • 08 Apr 2021 14:39

FluoGuide appoints new Certified Adviser

Copenhagen, Denmark, 18 March 2021 – FluoGuide A/S (“FluoGuide” or the “Company) appoints Svensk Kapitalmarknadsgransking AB as its new Cert...

Cision • 18 Mar 2021 10:59

FluoGuide acquires rights to photothermal therapy using FG001

Copenhagen, Denmark, 9 March 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that the Company has acquired worldw...

Cision • 09 Mar 2021 13:04

SEB initiates commissioned research on FluoGuide

Copenhagen, Denmark, 30 November 2020 – FluoGuide A/S (“FluoGuide” or the “Company”) has entered into an agreement with Skandinaviska Enskil...

Cision • 30 Nov 2020 20:11